ORI Updates

GS-15 Supervisory Health Scientist for the Division of Investigative Oversight will be removed for correction of technical errors and will be reposted as soon as possible.

OHRP has several useful educational resources for RCR professionals.

Research Misconduct Finding: Li Wang
ORI found that Dr. Wang engaged in research misconduct by recklessly including false data in National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH).

Join ORI's Division of Education and Integrity to help promote ORI’s education and integrity mission to leaders, executives, scientists, researchers in diverse fields, PHS research awardees, other federal agencies, state and local agencies, institutions of higher learning, and private sector institutions both nationally and internationally.  This job listing is open to all U.S. Citizens. Apply through USAJobs.gov.

The OHRP Exploratory Workshop is a new initiative to provide a forum for intellectual exchange within the research community on important issues related to human subjects protections.

The Office of Research Integrity announces the opportunity for non-federal public and private sector entities to co-sponsor ORI conferences or workshops. 

Dr. Christian Kreipke committed research misconduct in research supported by PHS grants.  Dr. Christian Kreipke requested a hearing before an Administrative Law Judge (ALJ) of the Departmental Appeals Board to dispute the findings. The ALJ issued a recommended decision to the Assistant Secretary for Health (ASH) granting summary judgment in favor of ORI and to impose a five-year debarment and a five-year ban...

Mr. Shiladitya Sen engaged in research misconduct by knowingly and intentionally falsifying and/or fabricating data reported in the following published paper, his Ph.D. thesis, a poster presentation, and his mentor’s grant applications submitted to NIGMS, NIH.

Maria Cristina Miron Elqutub engaged in research misconduct by recording dates and providing her own blood samples to cause these samples to be falsely labeled as samples from ninety-eight (98) study subjects in a cancer genetics study involving human blood samples.

The Office of Research Integrity (ORI) has appointed Dr. Ranjini Ambalavanar as Acting Director of the Division of Investigative Oversight. Since joining ORI in 2009, she has handled more than 100 allegations of research misconduct. She replaces Dr. Ann Hohmann, who successfully completed her 120-day detail appointment.